Pimicotinib is under clinical development by Abbisko Therapeutics and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase I drugs for Amyotrophic Lateral Sclerosis have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pimicotinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pimicotinib overview

Pimicotinib (ABSK-021) is under development for the treatment of advanced malignancies, tenosynovial giant cell tumors (TGCT), pancreatic cancer, triple negative breast cancer, non-small cell lung cancer, small cell lung cancer and other solid tumors, chronic graft versus host disease (GvHD) and amyotrophic lateral sclerosis (ALS). The therapeutic candidate is formulated as capsule and administered through oral route. It is acts by targeting CSF1R.

Abbisko Therapeutics overview

Abbisko Therapeutics (Abbisko) is a biopharmaceutical company. It discovers and develops of novel medicines to the treatment of cancers and other diseases. Its pipeline products include ABSK011, ABSK021 among others. ABSK011 developed for the treatment of advanced HCC with hyperactivation of FGF19/FGFR4 signaling. ABSK021 is for the treatment of adult patients with TGCT, pancreatic cancer, colorectal cancer, cGvHD and ALS. It offers services such as drug discovery development and clinical trials. It owns an integrated research and development center in Shanghai Zhangjiang Hi-Tech Park to conduct immune-oncology drug development activities. Abbisko is headquartered in Shanghai, China.

For a complete picture of Pimicotinib’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.